News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Lung & Bronchus → cancer profile · × Clear filters
[Series] The changing therapeutic landscape of small-cell lung cancer
A Lancet Series review synthesises the past decade of advances in small-cell lung cancer (SCLC) biology and the novel therapeutic strategies they are enabling. SCLC remains an exceptionally aggressive, highly proliferative malignancy that is frequently metastatic at diagnosis and rapidly becomes refractory to standard chemotherapy despite high initial response rates. The article maps how improved …
Zongertinib in HER2-Mutant Non–Small-Cell Lung Cancer
The NEJM has published a short item on zongertinib, a selective irreversible HER2 tyrosine kinase inhibitor, in HER2-mutant non-small-cell lung cancer — a molecular subset accounting for roughly 2–4% of NSCLC cases. Zongertinib belongs to a class of targeted agents developed specifically for this subset, which has until now been treated mainly with chemotherapy or with HER2-directed drugs used off…
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
TRI-611 is a novel brain-penetrant molecular glue degrader that induces selective degradation of ALK fusion proteins through a previously undescribed CRBN recruitment motif. In preclinical models the compound demonstrated anti-tumour activity against ALK-positive non-small-cell lung cancer, including CNS disease, positioning it as a potential new therapeutic approach for patients who progress on c…
Osimertinib, Chemotherapy, EGFR Mutations, and Advanced NSCLC
In a phase 3 randomized trial (JAMA, n=294), adding chemotherapy to first-line osimertinib in advanced EGFR-mutated non-small cell lung cancer with concurrent TP53 mutations extended investigator-assessed median progression-free survival from 15.6 to 34.0 months (HR 0.44; 95% CI 0.32-0.60). TP53 co-mutation is a known marker of inferior outcomes on EGFR-TKI monotherapy, and this is the first rando…
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
ASCO has published version 2026.3.2 of its living guideline for stage IV non-small cell lung cancer with oncogenic driver alterations (Journal of Clinical Oncology, Vol. 44, Issue 26, pp. e127-e139). The document collects recommendations for molecularly defined subgroups, including EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, NTRK and HER2 alterations, and is revised continuously as new data emerge…
Generative AI in neoantigen cancer vaccine design — a review of promise and limits
A review published in Biotechnology Advances (1 September 2026) sets out where generative models can assist in designing therapeutic neoantigen cancer vaccines: tumour antigen discovery, ranking candidates by predicted immunogenicity, and assembling multi-epitope constructs. The authors also state why clinical efficacy of these vaccines remains constrained — imperfect antigen prioritisation, incom…
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer
In a multicentre phase 1-2 dose-escalation and expansion study, 136 patients with previously treated advanced RAS-mutant non-small-cell lung cancer received the oral RAS inhibitor daraxonrasib at doses up to 300 mg once daily. Responses were seen in 31% of patients at doses up to 120 mg, 34% at 160-220 mg and 37% at 300 mg, while grade 3 or higher adverse events occurred in 54% and adverse events …
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer
The phase 3 SKYSCRAPER-01 trial (n=521) did NOT show a significant benefit from adding tiragolumab, an anti-TIGIT antibody, to atezolizumab as first-line treatment of PD-L1-high non-small cell lung cancer. Median progression-free survival was 7.0 versus 5.6 months (HR 0.78; 95% CI 0.63-0.97; P=.02, nonsignificant against the prespecified threshold) and median overall survival was 23.1 versus 16.9 …
Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems
A review in Nature Reviews Clinical Oncology discusses the global cancer burden using GLOBOCAN 2024 estimates: in 2024, 20.6 million people across 186 countries were diagnosed with cancer and 9.8 million died of it. Lung cancer remains the most common — 2.6 million new cases (12.8%) and 1.9 million deaths (19.1%) — ahead of female breast cancer (11.8% of cases), colorectal cancer (9.9%) and prosta…
Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial
This is a secondary safety and health-related quality-of-life analysis of the phase 3 ALINA trial (257 patients: 130 assigned alectinib, 127 chemotherapy after resection of ALK-positive non-small-cell lung cancer), not the efficacy report — the disease-free survival result was published previously. Alectinib's safety profile was manageable: serious adverse events occurred in 2 of 128 patients (2%)…